MOUNTAIN VIEW, Calif., Jan. 4, 2011 /PRNewswire/ — MAP
Pharmaceuticals, Inc. (Nasdaq:
MAPP) today announced that the company will present at the 29th
Annual J.P. Morgan Healthcare Conference on Tuesday, January 11,
2011 at 8:00 a.m. PT in San Francisco.
A live webcast of the presentation will be available on the
Investor Relations section of MAP Pharmaceuticals’ website at http://www.mappharma.com. A
replay will also be available within 24 hours for seven days
following the presentation.
About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging
biopharmaceutical company focused on developing and commercializing
new therapies to address undermet patient needs in neurology. The
Company is developing LEVADEX™ orally inhaled therapy for the
potential treatment of migraine and has reported positive results
from the efficacy portion of its Phase 3 trial of LEVADEX. In
addition, MAP Pharmaceuticals generates new pipeline opportunities
by applying its proprietary drug particle and inhalation
technologies to enhance the therapeutic benefits of proven drugs,
while minimizing risk by capitalizing on their known safety,
efficacy and commercialization history.